Description
Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-2; some of its antinociceptive and analgesic activities stems from its ability to also activate and desensitize transient receptor potential ankyrin 1 (TRPA1) channels. Etodolac also exhibits anticancer and chemopreventive activities, decreasing incidence of intraductal papillary carcinoma in vivo. Etodolac induces cell cycle arrest and inhibits growth in hepatocellular carcinoma cells, increasing expression of p21 and p27 and decreasing expression of CDK2, CDK4, Cdc2, cyclin A, and cyclin B1. Etodolac also displays radical scavenging activity in vitro.